MedeliX
Start asking

remdesivir

Veklury · ATC code J05AB16

Key facts
Active substance
remdesivir
Drug class
Direct acting antiviral
ATC code
J05AB16
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Veklury 100 mg powder for concentrate for solution for infusion
Marketing authorisation holder
Gilead Sciences Ireland UC
Information as of
2026-10-27

Key facts

Remdesivir is an antiviral nucleotide analogue given by intravenous infusion. It is used to treat COVID-19 in adults and children.

What it is used for

  • COVID-19 with pneumonia requiring supplemental oxygen (adults and children at least 4 weeks old weighing at least 3 kg)
  • COVID-19 not requiring supplemental oxygen in patients at increased risk of progressing to severe disease

Dosing

  • Adults and children weighing at least 40 kg: single loading dose of 200 mg on day 1, then 100 mg once daily by intravenous infusion
  • Children at least 4 weeks old weighing 3 kg to less than 40 kg: 5 mg/kg on day 1, then 2.5 mg/kg once daily
  • Requiring oxygen: daily for at least 5 days and not more than 10 days
  • Not requiring oxygen: daily for 3 days, started as soon as possible and within 7 days of symptom onset
  • No dose adjustment in renal or hepatic impairment; limited data in severe renal impairment

Contraindications

  • Hypersensitivity to the active substance or excipients

Important warnings

  • Hypersensitivity including infusion-related and anaphylactic reactions during and after administration; slower infusion may be considered
  • Use only where severe hypersensitivity reactions can be treated; monitor patients
  • Transaminase increases may occur

Side effects

  • Very common: increased transaminases (in healthy volunteers)
  • Common: nausea, headache, rash
  • Rare hypersensitivity; anaphylaxis and sinus bradycardia with unknown frequency

Interactions

  • Chloroquine or hydroxychloroquine: concomitant use not recommended (antagonism in vitro)
  • Remdesivir is a substrate of CYP3A4, OATP1B1 and P-gp; details in the full text

Pregnancy and breastfeeding

  • In the first trimester only if the woman's condition requires it; use in the second and third trimester may be considered
  • Excreted in breast milk in very small amounts; no clinical effect on the infant expected

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • VekluryGilead Sciences Ireland UC · EMEA/H/C/005622

Source: European Medicines Agency (EMA), product information

Turkey

  • VekluryGİLEAD SCİENCES İLAÇ TİC. LTD. ŞTİ. · 1 register entry

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 3 more European countries
Iceland
Veklury
Liechtenstein
Veklury
Norway
Veklury

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Veklury – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/veklury-epar-product-information_en.pdf
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  3. Wikidata (CC0): ATC J05AB.

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.